[Effects of the new peptide anxiolytic drug selank on the cardiovascular system functioning and respiration in cats].
Gan'shina. T S TS; Kozlovskiĭ. I I II
Key Findings
- Selank (300 mg/kg IV) caused a 32% drop in arterial pressure for 1–3 minutes.
- Cerebral blood flow increased by ~24% for 5–10 minutes before returning to baseline.
- Heart rate and respiratory rate were unchanged, and selank did not modify acetylcholine‑induced blood pressure drops.
Practical Outcomes
- The results are from anesthetized cats using a very high IV dose, so they don’t translate directly to human self‑experimentation. The study suggests selank can temporarily lower blood pressure without obvious heart or breathing side effects at this dose, but no actionable dosing or administration guidance for people can be derived.
Summary
In a cat study, an IV dose of the peptide selank briefly lowered blood pressure by about a third and raised brain blood flow, but didn’t change heart or breathing rates and didn’t affect how acetylcholine lowered blood pressure.
Abstract
The effects of the new heptapeptide anxiolytic drug selank (300 mg/kg, i.v.) on the arterial pressure (AP), cerebral blood flow, heart rhythm, respiration, and the AP depression induced by acetylcholine injections was recorded in narcotized male cats. Selank produced a 32 +/- 4.3% decrease in the AP for the first 1-3 min after injection. The drug also induced a 24 +/- 2.8% increase in the cerebral blood flow for the first 5 - 10 min upon injection and then the blood flow was gradually restored on the initial level. The heart rate and the respiratory rate were not affected by the drug injections. Nor did selank influence the AP depression in response to the acetylcholine introduction.
Study Information
pubmed
2005